Iloperidone for schizophrenia

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 12, 2010, Pages 2087-2093

  Rado, Jeffrey ^a   Janicak, Philip G ^a  

^a RUSH UNIVERSITY   (United States)

Author keywords

Antipsychotic; Dopamine antagonist; Efficacy; Iloperidone; Schizophrenia

Indexed keywords

GLUCOSE; HALOPERIDOL; ILOPERIDONE; PALIPERIDONE; PLACEBO; RISPERIDONE; SEROTONIN 2A RECEPTOR; ZIPRASIDONE; DOPAMINE RECEPTOR BLOCKING AGENT; ISOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE; SEROTONIN ANTAGONIST;

ANXIETY; BINDING AFFINITY; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONVULSION; DIZZINESS; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HUMAN; INSOMNIA; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOSIS; QT PROLONGATION; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; WEIGHT GAIN; XEROSTOMIA; ANIMAL; GENETICS; PHARMACOGENETICS; TREATMENT OUTCOME;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE ANTAGONISTS; DRUG APPROVAL; HUMANS; ISOXAZOLES; PHARMACOGENETICS; PIPERIDINES; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 77954806555     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.502889     Document Type: Review

References (17)

1. Ichikawa J, Li Z, Dai J, et al. Atypical antipsychotic drugs, quetiapine, iloperidone and melperidone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Res 2002;956:349-357
2. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology 2001;25:904-914
3. Subramanian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychoharmacol Biol Psychiatry 2002;26:553-560
4. Potkin SG, Litman RE, Torres R, et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008;28:S4-11
5. Kay ST, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;12:261-276
6. Overall JE, Gorham DR. The brief psychiatric rating scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988;24:97-99
7. Guy W. ECDEU assessment manual for psychopharmacology-revised (DHEW Publ. No. ADM 76-338). Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD: USA; 1976. p. 218-222
8. Cutler AJ, Kalali AH, Weiden PJ, et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol 2008;28(Suppl 1):S20-8
9. Cutler AJ, Bishop JR. An update on the investigational antipsychotic iloperidone: an expert interview with Andrew J. Cutler, MD. Medscape Psychiatry and Mental Health. 2008. Available from: http://medscape. com/viewarticle/571878 [Last accessed 21 September 2009]
10. Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28(Suppl 1):S29-35
11. Weiden PJ, Cutler AJ, Polymeropoulos MH, et al. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials. J Clin Psychopharmacol 2008;28(Suppl 1):S12-19
12. Chouinard G, Ross-Chouinard A, Annable L, et al. The extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7:233
13. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
14. Volpi S, Potkin SG, Malhotra AK, et al. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009;70:801-819
15. Volpi S, Heaton C, Mack K, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry 2009;14:1024-1031
16. Yan J. FDA reverses earlier decision, approves schizophrenia drug. Psychiatr News 2009;44:2
17. Hill CL, Phadke D, Boyce KM. Four-week iloperidone depot injectable: safety and pharmacokinetic profile in patients with schizophrenia and schizoaffective disorder [Poster NR4-022]. American Psychiatric Association 2008 Annual Meeting; 3 - 8 May 2008; Washington, C, USA. In: New Research Abstracts. Arlington, VA: American Psychiatric Association, 2008. p. 169-170